Skip to content
IP + Technology Law
Home  »  News & Insights  »  Publications

Lessons From The 1st Biopharma Inter Partes Reviews | Law360

April 16, 2015  | Eli A. Loots, Ph.D.

Recently, the Patent Trial and Appeal Board issued its first set of final written decisions in three inter partes reviews relating to molecules in the large molecule biopharma space (IPR2013-00534, IPR2013- 00535 and IPR2013-00537). Biosimilar companies will no doubt be looking to these decisions as a roadmap for clearing patent landscapes for their own biosimilar products in the coming years. Read more below or download the PDF.

Lessons From The 1st Biopharma Inter Partes Reviews from Knobbe Martens Olson & Bear

Related Links

Practice Areas

Industries

News & Insights

Publications
May 2026
USPTO Director Signals Continued Pro-Patent Discretionary Denial Policy at the Patent Trial and Appeal Board
Key Takeaway: In a precedential decision in Magnolia Medical Technologies, Inc. v. Kurin, Inc., USPTO Director Squires denied IPR institution and reinforced the policy framework for discretionary denial at the...
News
Mar 2026
Sheila Swaroop Comments on USPTO Memo on U.S. Manufacturing Factors in AIA Reviews
In the Law360 article “Manufacturing Factor Adds More New Twists to AIA Cases,” Knobbe Martens partner Sheila Swaroop weighed in on the U.S. Patent & Trademark Office’s latest memo regarding...
Publications
May 2026
In Law360 Column, Sean Murray and Jeremiah Helm Explore Limits of Retroactivity in IPR Proceedings
In the latest installment of their monthly Law360 column covering recent noteworthy Federal Circuit decisions, Knobbe Martens partners Sean Murray and Jeremiah Helm discussed the court’s opinion on retroactivity in...